Hôpital Charles LeMoyne
Hôpital Charles LeMoyne
Longueuil, Quebec, Canada1 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months. | Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 3 | 2025-03-04 | NCT06855589 |